{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:46:53Z","timestamp":1776260813029,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T00:00:00Z","timestamp":1649548800000},"content-version":"vor","delay-in-days":99,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.lrr.2022.100314","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T11:50:20Z","timestamp":1649850620000},"page":"100314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Daratumumab as a Frontline Immunosuppression for Pure Red Cell Aplasia after Major ABO-mismatched Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0176-418X","authenticated-orcid":false,"given":"Thiti","family":"Asawapanumas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5258-2140","authenticated-orcid":false,"given":"Chantiya","family":"Chanswangphuwana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8270-5308","authenticated-orcid":false,"given":"Phandee","family":"Watanaboonyongcharoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7912-1996","authenticated-orcid":false,"given":"Ponlapat","family":"Rojnuckarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udomsak","family":"Bunworasate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lrr.2022.100314_bib0001","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/bjh.12210","article-title":"Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation","volume":"160","author":"Aung","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.lrr.2022.100314_bib0002","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2141.2005.05364.x","article-title":"Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation","volume":"128","author":"Griffith","year":"2005","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.lrr.2022.100314_bib0003","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.bbmt.2016.02.008","article-title":"Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia","volume":"22","author":"Aung","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.lrr.2022.100314_bib0004","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1600-0609.2004.00320.x","article-title":"Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion","volume":"73","author":"Verholen","year":"2004","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.lrr.2022.100314_bib0005","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/bmt.2011.176","article-title":"Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib","volume":"47","author":"Poon","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.lrr.2022.100314_bib0006","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1182\/blood.V126.23.5453.5453","article-title":"Ayad Hamdan. Pure Red Cell Aplasia after ABO-Mismatched Allogeneic Stem Cell Transplantation Treated with Therapeutic Plasma Exchange and Rituximab","volume":"126","author":"JEA","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.lrr.2022.100314_bib0007","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.bbmt.2018.04.022","article-title":"Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation","volume":"24","author":"Busca","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.lrr.2022.100314_bib0008","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25515","article-title":"Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab","volume":"94","author":"Bathini","year":"2019","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.lrr.2022.100314_bib0009","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMoa1807438","article-title":"Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation","volume":"379","author":"Chapuy","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lrr.2022.100314_bib0010","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/s41409-019-0664-4","article-title":"Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation","volume":"55","author":"Rautenberg","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.lrr.2022.100314_bib0011","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/ejh.13343","article-title":"Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab","volume":"104","author":"Salas","year":"2020","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.lrr.2022.100314_bib0012","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00277-019-03624-y","article-title":"Different prognostic effects of core-binding factor positive AML with Korean AML registry data","volume":"98","author":"Shin","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.lrr.2022.100314_bib0013","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.lrr.2022.100314_bib0014","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.3389\/fimmu.2018.02616","article-title":"Blood Transfusion Management for Patients Treated with Anti-CD38 Monoclonal Antibodies","volume":"9","author":"Lancman","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.lrr.2022.100314_bib0015","article-title":"Daratumumab rapidly reduces high-titre factor VIII inhibitors in haemophilia A patients during life-threatening haemorrhages","author":"Moonla","year":"2020","journal-title":"Haemophilia"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048922000267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048922000267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:09:50Z","timestamp":1761959390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048922000267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":15,"alternative-id":["S2213048922000267"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2022.100314","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daratumumab as a Frontline Immunosuppression for Pure Red Cell Aplasia after Major ABO-mismatched Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2022.100314","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100314"}}